MorphoSys AG announced that its partner Novartis will conduct a phase 2 clinical trial of the HuCAL antibody bimagrumab in obese patients with type 2 diabetes. This new study will join phase 2 clinical trials of bimagrumab currently ongoing in patients with sarcopenia and after hip fracture surgery. Reportedly, this randomised, subject-blinded and investigator-blinded study will enrol 60 obese adult patients with type 2 diabetes to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab compared to placebo. This study is not yet open for enrolment.